USPTO serial 97372322
CANARY
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- FIRST, VIVIAN M
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with CANARY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Vancouver, BC, CA
Vancouver, BC, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kevin S. Costanza
Kevin S. Costanza SEED IP LAW GROUP LLP701 FIFTH AVENUESUITE 5400SEATTLE, WA 98104Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 010 | Angioplasty rings which measure blood flow, blood pressure and blood volume; artificial heart valves; Cardiovascular devices, namely, synthetic coronary stent grafts; coronary stents; implantable medical devices adapted for recording and transferring internal patient data and for monitoring the integrity and function of the device during use; Implants consisting of artificial materials; Joint prostheses; joint prostheses adapted for recording and transferring internal patient data and for monitoring the integrity and function of the implanted prosthesis during use; medical, surgical and orthopaedic implants made of artificial materials; artificial bone and joint prosthesis for implantation; medical devices, namely, medical sensors that are implanted or inserted into the human body used to continuously monitor the concentration of glucose in the human body and accessories therefor, namely, receivers, sensor housings and sensor insertion devices; medical devices, namely, medical sensors that are implanted or inserted into the human body used to continuously monitor bleeding in the human body and accessories therefor, namely, receivers, sensor housings and sensor insertion devices; Non-implantable and portable medical and diagnostic devices, namely, patient monitors and wearable patient monitor patches and ingestible patient sensors for monitoring, measuring and capturing physiologic data, environmental data, treatment data, data related to medications, pharmaceuticals, and supplements, and data transmitted by medical devices; medical devices, namely, wireless receivers and transmitters used for capturing patient physiologic data, patient environmental data, patient treatment data, data related to patient medications, pharmaceuticals, and supplements, and patient data transmitted by medical devices, ingestible sensors, implants, and conductive packaging and labels; Implantable medical devices, namely, patient monitors for monitoring and capturing physiologic data, environmental data, treatment data, data related to medications, pharmaceuticals, and supplements, and data transmitted by medical devices; orthopedic joint implants made of artificial materials; sensors specially adapted for use with medical devices for determining integrity, function and usage of integrated component parts in the nature of batteries and remote power sources, and also featuring a microcontroller, wireless transceiver, and memory electronics for use in recording and transferring internal patient data to a medical device external to the body comprised of a wireless transceiver, power source, microcontroller, and primary transceiver for communication with a medical implant; medical surgical system consisting primarily of an artificial orthopedic implant, a wearable medical device, a charger for the wearable medical device, and computer hardware and software for providing kinematic data and information to medical professionals; medical monitoring systems for aneurism stent graph comprised primarily of medical sensors for measuring blood pressure, blood flow volume, and heart rate, stent graph leaks, and also featuring computer hardware and integrated software for communicating and transmitting sensor data; medical monitoring systems for hypertension monitoring comprised primarily of medical sensors for measuring blood pressure, blood flow volume, and heart rate, and also featuring computer hardware and integrated software for communicating and transmitting sensor data; medical monitoring systems for in vivo cardiovascular blood pressure monitoring comprised primarily of medical sensors for measuring blood pressure, blood flow volume, and heart rate, and also featuring computer hardware and integrated software for communicating and transmitting sensor data; medical monitoring systems specially adapted for use with medical devices for monitoring the integrity and function of a medical implant comprised primarily of sensors for determining battery integrity, life and usage, sensor and system integrity, life and usage, and medical implant integrity, functionality and usage, and also featuring computer hardware and integrated software for communicating and transmitting sensor data; wearable medical device consisting of patient sensors for monitoring, measuring and capturing kinematic data; wearable medical device consisting of patient sensors for monitoring, measuring and capturing physiologic data | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 21, 2026 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Sep 21, 2026 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 11, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 10, 2026 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Jun 8, 2026 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jan 13, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 12, 2026 | EXT5 | SOU EXTENSION 5 FILED | — |
| Aug 9, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 8, 2025 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Aug 8, 2025 | EXT4 | SOU EXTENSION 4 FILED | — |
| Aug 8, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 6, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 6, 2025 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Feb 6, 2025 | EXT3 | SOU EXTENSION 3 FILED | — |
| Feb 5, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 14, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 14, 2024 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Aug 14, 2024 | EXT2 | SOU EXTENSION 2 FILED | — |
| Aug 14, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 9, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 8, 2024 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Feb 8, 2024 | EXT1 | SOU EXTENSION 1 FILED | — |
| Feb 8, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 15, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 20, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 20, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 31, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 12, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 12, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 12, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 12, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 12, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 5, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 4, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 4, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 7, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 7, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 7, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 1, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 26, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 23, 2022 | NWAP | NEW APPLICATION ENTERED | — |